| 30.92 2.71 (9.61%) | 09-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 36.62 |
1-year : | 42.78 |
| Resists | First : | 31.36 |
Second : | 36.62 |
| Pivot price | 25.89 |
|||
| Supports | First : | 24.82 |
Second : | 20.78 |
| MAs | MA(5) : | 27.6 |
MA(20) : | 26 |
| MA(100) : | 19.27 |
MA(250) : | 22.59  |
|
| MACD | MACD : | 1.7 |
Signal : | 1.5 |
| %K %D | K(14,3) : | 92.1 |
D(3) : | 76.5 |
| RSI | RSI(14): 76.2 |
|||
| 52-week | High : | 34.11 | Low : | 14.18 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CAI ] has closed It is unclear right now based on current values. 43.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 31.4 - 31.52 | 31.52 - 31.63 |
| Low: | 28.21 - 28.35 | 28.35 - 28.48 |
| Close: | 30.66 - 30.91 | 30.91 - 31.12 |
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
Thu, 17 Sep 2026
Caris Life Sciences (CAI) director plans 400,000-share sale - Stock Titan
Thu, 17 Sep 2026
Caris Life Sciences: Diagnostics Growth With Room To Run (NASDAQ:CAI) - Seeking Alpha
Wed, 16 Sep 2026
Caris Life Sciences, Inc. (CAI) Soars 9.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Tue, 15 Sep 2026
Caris Life Sciences (NASDAQ:CAI) Trading 3.9% Higher - What's Next? - marketbeat.com
Mon, 14 Sep 2026
New investor pitch from Caris Life Sciences (CAI) set for Morgan Stanley healthcare event - Stock Titan
Sat, 12 Sep 2026
Amundi Buys 1,197,392 Shares of Caris Life Sciences, Inc. $CAI - marketbeat.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 283 (M) |
| Shares Float | 135 (M) |
| Held by Insiders | 48.5 (%) |
| Held by Institutions | 55.7 (%) |
| Shares Short | 14,950 (K) |
| Shares Short P.Month | 11,730 (K) |
| EPS | 9.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.08 |
| Profit Margin | 10.6 % |
| Operating Margin | 10.2 % |
| Return on Assets (ttm) | 8.7 % |
| Return on Equity (ttm) | 20.1 % |
| Qtrly Rev. Growth | 45.4 % |
| Gross Profit (p.s.) | 2.44 |
| Sales Per Share | 3.5 |
| EBITDA (p.s.) | 0.61 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 169 (M) |
| Levered Free Cash Flow | 63 (M) |
| PE Ratio | 3.22 |
| PEG Ratio | 0 |
| Price to Book value | 14.79 |
| Price to Sales | 8.83 |
| Price to Cash Flow | 51.85 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|